A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 213 participants.
Also called NCT01698775
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 213 participants
- Sponsor
- Registry
-
NCT01698775 -
2012-002332-85
-
- Other papers using this trial's data
- A randomised, double-blind, trial of the safety and efficacy of omarigliptin (a once-weekly DPP-4 inhibitor) in subjects with type 2 diabetes and renal impairment
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT01698775. Randomized; triple masking; primary purpose treatment. Start 2012-10-02 (actual); primary completion 2016-01-19 (actual). Results posted on 2017-02-23.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019)
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Omarigliptin
- Intervention (Drug)
- Placebo to omarigliptin
- Intervention (Drug)
- Glipizide
- Intervention (Drug)
- Placebo to glipizide
- Intervention (Biological)
- Insulin
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct01698775- Content hash
d50cbeae00c3789ec328cc5690e130f84450c48ab64bfdcc326949494ef69a04